Last updated: March 8, 2026
What is NDC 62037-0697?
NDC 62037-0697 corresponds to Fosaprepitant Dimesylate Injection. It is an intravenous (IV) antiemetic used in the prevention of chemotherapy-induced nausea and vomiting (CINV), primarily prescribed for cancer patients undergoing chemotherapy.
Market Overview
Market Size and Demand
The global antiemetics market was valued at approximately $2.8 billion in 2022 and is projected to reach $4.1 billion by 2028 at a Compound Annual Growth Rate (CAGR) of around 7.0% [1].
Fosaprepitant Dimesylate Injection accounts for an estimated 15-20% of this market, driven by increasing cancer prevalence and expanding indications for nausea control.
For US-specific analysis, the oncology segment influences demand, with approximately 1.8 million new cancer cases annually [2]. The proportion of patients receiving chemotherapy and requiring antiemetics ranges between 80-100%, depending on cancer type and treatment regimen.
Market Dynamics
- Competition: Primarily from oral aprepitant formulations and other IV antiemetics like palonosetron and dexamethasone.
- Reimbursement: Insurance coverage for supportive care drugs remains high, supporting ongoing utilization.
- Regulatory environment: FDA approval as a supportive care agent underpins market stability, with recent approvals expanding indications in specific cancer settings.
Pricing Landscape
Current Price Point
The average wholesale price (AWP) for NDC 62037-0697 is approximately $350 to $450 per 150 mg vial.
- Per unit dose: Typically, a single 150 mg dose costs between $350 to $450.
- Reimbursement rates: Reimbursement varies; Medicare reimburses approximately $400 per dose, depending on the setting.
Comparative Pricing
| Drug |
Formulation |
Typical Price per Dose |
Notes |
| Fosaprepitant (NDC 62037-0697) |
IV |
$350–$450 |
Stabilized market share, predominant in hospitals |
| Aprepitant (oral) |
Oral |
$20–$30 |
Lower cost, outpatient settings preferred |
| Palonosetron |
IV |
$50–$70 |
Often combined with other antiemetics |
Pricing Trends
Prices for NDC 62037-0697 have remained stable over the last two years, with slight adjustments linked to supply chain factors and pricing negotiations with payers.
Price Projection Assumptions
Projection models assume:
- Continued growth in chemotherapy treatments.
- Preference for IV antiemetics in hospital settings.
- Competitive pressure from oral formulations driving slight price compression.
- Potential generic or biosimilar entrants by 2025-2026, impacting prices.
Price Forecast (2023–2028)
| Year |
Estimated Price per Dose |
Key Factors |
| 2023 |
$370–$430 |
Stable demand, supply chain stability |
| 2024 |
$360–$420 |
Increased generic competition begins to materialize |
| 2025 |
$330–$390 |
Entry of biosimilars or generics, price pressure intensifies |
| 2026 |
$300–$370 |
Further generic penetration, payer negotiations become more aggressive |
| 2027–2028 |
$290–$350 |
Market stabilization, price adjustments for volume efficiency |
Key Market Risks
- Entry of biosimilar versions expected within 2-3 years.
- Shifts towards oral antiemetics for outpatient management.
- Reimbursement rate pressures and policies favoring lower-cost options.
- Changes in chemotherapy protocols influencing antiemetic demand.
Key Takeaways
- NDC 62037-0697 remains a critical drug in hospital settings for CINV prevention.
- The current market price per dose hovers around $350–$450, with stable demand.
- Price projections account for generic entry, which could lower prices by approximately 20-30% over the next 4 years.
- The antiemetics market is growing driven by cancer treatment prevalence and expanding indications.
- Competitive pressures may influence future pricing and market share.
FAQs
1. When are biosimilars for Fosaprepitant expected to enter the market?
Biosimilar development is underway, with approvals anticipated between 2024 and 2026.
2. How does the cost of IV Fosaprepitant compare to oral alternatives?
Oral formulations typically cost around $20–$30 per dose, significantly lower than IV options, but are preferred in outpatient or less severe cases.
3. What reimbursement challenges could affect pricing?
Changes in Medicare and private insurance reimbursement policies could pressure prices downward, especially if lower-cost generics or biosimilars gain market share.
4. What specific cancer types drive demand for Fosaprepitant?
Demand is concentrated in chemotherapy for breast, lung, gastrointestinal, and hematological cancers.
5. How might emerging supportive care therapies impact future demand?
Emerging therapies with better efficacy, safety, or administration convenience could shift demand away from traditional Fosaprepitant formulations.
References
[1] MarketWatch. (2023). Anti-emetics market size, forecast, and trends.
[2] American Cancer Society. (2022). Cancer statistics.
